Skip to main content
. Author manuscript; available in PMC: 2014 Aug 7.
Published in final edited form as: Cancer Biol Ther. 2007 Jun 5;6(9):1360–1367. doi: 10.4161/cbt.6.9.4541

Figure 3.

Figure 3

Decrease PSA levels in five patients after stopping CEP-701. Lines represent Normalized PSA levels plotted vs. time for each patient. Day that CEP-701 was stopped is by the gray circle. Two patients completed study on scheduled day 84, two patients ended study early due to toxicity and one patient continued on study until day 154 due to stable PSA (i.e., <50% increase in PSA).